Alkermes plc (NASDAQ:ALKS) Stock Has Consensus Target Price of $54.47 According to Analysts

Posted by Stanley Muller on Oct 20th, 2026

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the nineteen analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $54.47.

Several equities analysts recently issued reports on ALKS shares. TD Cowen restated a “buy” rating on shares of Alkermes in a research report on Monday, September 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a report on Tuesday, July 28th. Robert W. Baird lifted their target price on shares of Alkermes from $58.00 to $61.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Truist Financial initiated coverage on Alkermes in a research report on Friday. They set a “buy” rating and a $55.00 target price on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Alkermes in a research note on Monday, September 21st.

Check Out Our Latest Stock Analysis on Alkermes

Insider Transactions at Alkermes

In other news, Director Nancy Lynn Md Snyderman sold 44,472 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $50.35, for a total transaction of $2,239,165.20. Following the completion of the transaction, the director directly owned 15,395 shares of the company’s stock, valued at $775,138.25. This trade represents a 74.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Gaffin sold 2,034 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $41.03, for a total value of $83,455.02. Following the completion of the transaction, the executive vice president directly owned 221,388 shares of the company’s stock, valued at approximately $9,083,549.64. This trade represents a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 76,150 shares of company stock worth $3,752,181. Corporate insiders own 4.59% of the company’s stock.

Institutional Trading of Alkermes

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its holdings in shares of Alkermes by 2.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,522,378 shares of the company’s stock worth $159,850,000 after buying an additional 109,595 shares in the last quarter. Commodore Capital LP raised its position in shares of Alkermes by 18.3% in the 1st quarter. Commodore Capital LP now owns 4,200,000 shares of the company’s stock worth $148,512,000 after buying an additional 650,000 shares during the period. First Trust Advisors LP lifted its stake in shares of Alkermes by 104.2% in the 1st quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock valued at $104,976,000 after purchasing an additional 1,514,783 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in Alkermes by 35.0% during the first quarter. Affinity Asset Advisors LLC now owns 1,350,000 shares of the company’s stock valued at $47,736,000 after buying an additional 350,000 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in Alkermes by 1.1% during the 1st quarter. Principal Financial Group Inc. now owns 958,016 shares of the company’s stock worth $33,875,000 after purchasing an additional 10,393 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Performance

Shares of ALKS opened at $42.97 on Friday. The company has a current ratio of 2.30, a quick ratio of 1.85 and a debt-to-equity ratio of 0.82. The firm has a market cap of $7.21 billion, a PE ratio of 95.86 and a beta of 0.32. Alkermes has a 12-month low of $27.00 and a 12-month high of $55.67. The company’s 50 day simple moving average is $44.89 and its 200-day simple moving average is $43.77.

About Alkermes

(Get Free Report)

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.